| 靶点: |
Ki: 1.6 nM (α1D adrenoceptor) |
| 体内研究: |
ADRA1D receptor antagonist 1 (4.4 µg/kg; i.v.) dose-dependently decreases the non-voiding bladder contractions during the urinary storage phase in rats with BOO. |
| 参考文献: |
1. Sakauchi N, et al. Discovery of 5-Chloro-1-(5-chloro-2-(methylsulfonyl)benzyl)-2-imino-1,2-dihydropyridine-3-carboxamide (TAK-259) as a Novel, Selective, and Orally Active α1D Adrenoceptor Antagonist with Antiurinary Frequency Effects: Reducing Human Ethe |
| 保存条件: |
-80℃,避光,干燥(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.966 ml |
14.828 ml |
29.656 ml |
| 5 mM |
0.593 ml |
2.966 ml |
5.931 ml |
| 10 mM |
0.297 ml |
1.483 ml |
2.966 ml |
| 50 mM |
0.059 ml |
0.297 ml |
0.593 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |